查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857917

卡波西氏肉瘤市场按患者族群、治疗方法、疾病类型、分布地点、最终用户和销售管道划分－2025-2032年全球预测

Kaposi Sarcoma Market by Patient Population, Treatment Modality, Disease Type, Distribution Site, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，卡波西氏肉瘤市场规模将成长至 1.9677 亿美元，复合年增长率为 3.84%。

主要市场统计数据
基准年 2024 1.4555亿美元
预计年份：2025年 1.5127亿美元
预测年份：2032年 1.9677亿美元
复合年增长率 (%) 3.84%

卡波西氏肉瘤策略框架整合了病毒学、免疫学、不断发展的临床实践以及以患者为中心的护理的多学科必要性。

卡波西氏肉瘤是感染疾病、肿瘤学和免疫学之间的重要交叉领域，需要临床诊疗、药物研发和卫生系统等各方面进行整合思考。本文将卡波西氏肉瘤纳入现代临床实践，重点在于阐述其发病机制及其与人类疱疹病毒8型（HHV-8）的关联，以及宿主免疫状态与病变生物学之间的相互作用。近几十年来，联合治疗抗逆转录病毒疗法已显着降低了许多地区地方性卡波西氏肉瘤的发生率，但该疾病仍存在于包括晚髮型HIV感染者、免疫力缺乏但非HIV感染者以及长期接受免疫抑制治疗的移植受者在内的不同人群中。

在卡波西氏肉瘤治疗中，临床、治疗和系统层面的变化将重新定义病患诊疗路径、治疗模式和就医动态。

卡波西氏肉瘤的治疗格局正经历着多重因素的交会转变，这些转变正在重塑临床路径和商业性机会。爱滋病毒诊断技术的进步以及对早期抗逆转录病毒疗法的重视，正在改变许多高所得国家卡波西氏肉瘤的发病率，并改变肿瘤科和皮肤科门诊患者群体的组成。同时，移植手术的普及和强效免疫抑制剂使用量的增加，使得异位卡波西氏肉瘤病例的相对比例上升，这通常需要不同的治疗方法以及与移植团队更紧密的合作。

2025年美国关税调整将如何影响卡波西氏肉瘤治疗的供应链、筹资策略、临床营运和取得动态

美国将于2025年实施的累积关税将对卡波西氏肉瘤治疗相关的药品供应链、筹资策略和定价动态连锁反应。对原料药和成品抗癌药物征收进口关税可能会增加脂质体蒽环类药物、细胞週期蛋白烷类药物和某些辅助治疗药物等药品的到岸成本，进而可能加重医院的配药和急诊预算负担。因此，采购团队正在重新评估筹资策略，包括强调合约多元化、近岸外包和签订长期供应商协议，以降低价格波动和交货风险。

一个可操作的多维度细分框架，将患者群体、治疗方式、疾病类型、分销点、最终用户和销售管道联繫起来，以製定有针对性的策略。

细緻入微的患者分层框架对于理解治疗需求和设计针对性介入措施至关重要。透过区分 HIV 感染者、免疫力缺乏HIV 的患者以及器官移植受者，对患者群体进行分层可以明确临床驱动因素。例如，HIV 感染者通常需要抗逆转录病毒治疗和机会性感染疾病的综合管理，而器官移植受者则需要在抗肿瘤疗效和移植器官保护之间取得平衡。

卡波西氏肉瘤的区域视角在美洲、中东/非洲和亚太地区，流行病学、卫生系统能力和医疗服务取得策略方面存在共通性。

区域动态对临床实践、医疗服务取得和治疗方案的演变有着深远的影响。在美洲，抗逆转录病毒的广泛应用使得高资源地区地方性卡波西氏肉瘤的发生率下降。这导致对爱滋病-肿瘤综合服务、脂质体化疗门诊输注能力以及能够应对合併症和社会健康决定因素的支持性护理网络的需求集中起来。该区域南北之间的差异也使得必须建立有针对性的推广和资金筹措机制，以确保医疗服务的连续性。

製药生物技术策略如何协调研发、生产、伙伴关係和病患支持，以满足卡波西氏肉瘤的临床需求和实际可近性

公司层面的动态反映了传统肿瘤产品组合、新兴免疫疗法计画以及专注于病毒肿瘤学和标靶递送系统的生物技术公司的多元化发展。在脂质体和细胞毒性药物领域拥有成熟经验的现有製药公司继续支持标准治疗方法，并维持脂质体细胞週期蛋白和紫杉烷类药物的生产规模。同时，生物製药创新者正致力于开发免疫调节方法、主导生物标记的适应症以及新一代递送平台，以提高卡波西氏肉瘤患者的疗效和耐受性。

针对卡波西氏肉瘤，企业可采取切实可行的策略行动来加强供应链、优先进行转化研究，并使商业模式与临床实际情况相符。

产业领导者应采取一系列切实可行的措施，在推动治疗创新的同时，保障病患的用药可及性。首先，透过多元化采购、区域性生产伙伴关係以及长期采购协议来增强供应链韧性，可以确保脂质体细胞週期蛋白类药物等核心药物的稳定供应，同时降低关税和区域经济风险。其次，投资于转化生物标记计画和可操作的临床试验，以识别哪些患者能够查核点抑制剂和干扰素-α治疗中获益，可以降低监管干预的风险，并为有针对性的医疗保险报销谈判提供支持。

透明且多维度的调查方法，结合临床文献、监管分析、试验註册库和相关人员访谈，确保获得可靠且可操作的见解。

本研究采用三角测量法进行综合分析，结合了同行评审的临床文献、监管指导文件、公开的临床试验註册库以及与多学科临床医生和供应链专家的结构化访谈。文献分析着重于与卡波西氏肉瘤相关的病毒学、肿瘤治疗方法和放射技术的最新进展，而监管审查则探讨了代表性司法管辖区的核准、同情用药政策和报销框架。

一份简明扼要的综述强调了个人化医疗、灵活的给药策略和转化投资对于改善卡波西氏肉瘤治疗效果的必要性

卡波西氏肉瘤的临床和商业性挑战复杂多样，需要跨领域、跨地区采取整合的、实证的应对措施。虽然抗病毒疗法改善了许多患者的预后，但该疾病仍局限于一部分特殊人群，需要量身定制的临床治疗方案。全身性化疗、新兴免疫疗法、放射技术和外科手术方案之间的相互作用，凸显了製定个人化治疗方案和多学科协作的必要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • PD-1和PD-L1免疫查核点抑制剂在难治性卡波西氏肉瘤治疗的应用日益广泛
  • 扩大平价学名药紫杉醇和脂质体阿霉素的生产，以服务卡波西氏肉瘤高发生率的低收入市场。
  • 局部应用Sirolimus和局部製剂用于治疗卡波西氏肉瘤的局部皮肤病变
  • 开发用于远端监测卡波西肉瘤进展的数位皮肤病学和行动成像平台
  • 扩大HHV-8分子诊断在卡波西氏肉瘤早期检测和个体化管理的应用
  • 启动一项多中心临床试验，评估抗血管新生药物和新型Thalidomide衍生物在治疗卡波西氏肉瘤的疗效
  • 製药公司与全球卫生组织建立策略伙伴关係，以扩大撒哈拉以南非洲地区卡波西氏肉瘤的药物取得途径
  • 应用基因编辑和病毒潜伏期标靶治疗破坏卡波西氏肉瘤患者体内HHV-8的持续存在

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 卡波西氏肉瘤患者族群市场

  • HIV阳性患者
  • 免疫力缺乏的非爱滋病患者
  • 移植患者

9. 卡波西氏肉瘤市场依治疗方法划分

  • 化疗
    • 脂质体细胞週期蛋白
    • 紫杉烷类抗癌药物
  • 免疫疗法
    • 查核点抑制剂
    • α干扰素
  • 放射线治疗
    • 近距离放射治疗
    • 外束辐射
  • 手术治疗
    • 整形手术
    • 病灶切除

第十章 卡波西氏肉瘤市场（依疾病类型划分）

  • 传统的
  • 地方性疾病
  • 时尚
  • 医源性

第十一章 卡波西氏肉瘤市场（依通路划分）

  • 皮肤
  • 黏膜
  • 内臟器官

第十二章 卡波西氏肉瘤最终用户市场

  • 医院
  • 门诊病人设施
  • 专科诊所

第十三章 卡波西氏肉瘤市场（依销售管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 卡波西氏肉瘤市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 卡波西氏肉瘤市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 卡波西氏肉瘤市场（按国家/地区划分）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Johnson & Johnson
    • Bristol-Myers Squibb Company
    • Roche Holding AG
    • Novartis AG
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Gilead Sciences, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • AbbVie Inc.
Product Code: MRR-C002B1C994FA

The Kaposi Sarcoma Market is projected to grow by USD 196.77 million at a CAGR of 3.84% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 145.55 million
Estimated Year [2025] USD 151.27 million
Forecast Year [2032] USD 196.77 million
CAGR (%) 3.84%

A strategic framing of Kaposi sarcoma that integrates virology, immunology, evolving clinical practice, and multidisciplinary imperatives for patient-centered care

Kaposi sarcoma remains an instructive junction between infectious disease, oncology, and immunology, demanding integrated thinking across clinical care, drug development, and health systems. This introduction situates the condition within contemporary practice by emphasizing its etiologic link to human herpesvirus 8 and the interplay between host immune status and lesion biology. Over recent decades, combination antiretroviral therapy dramatically reduced epidemic Kaposi sarcoma incidence in many settings, yet the disease persists in diverse populations, including people living with HIV who are late presenters, immunocompromised non-HIV patients, and transplant recipients under chronic immunosuppression.

Beyond epidemiology, the clinical spectrum of Kaposi sarcoma ranges from isolated cutaneous lesions to life-limiting visceral involvement, and this heterogeneity shapes diagnostic priorities and therapeutic decision-making. Therefore, multidisciplinary coordination among infectious disease specialists, oncologists, transplant teams, and dermatologists is essential for individualized care. Equally, clinical trials and real-world evidence are increasingly focused on optimizing sequencing of systemic and local therapies, integrating emerging immunotherapies, and refining endpoints that capture functional and quality-of-life outcomes.

As stakeholders navigate constrained budgets and evolving regulatory expectations, the need for precise patient stratification, pragmatic trial designs, and partnerships that accelerate translational discoveries has never been greater. This introductory context sets the stage for deeper analysis of the transformative shifts, policy impacts, segmentation nuances, and regional considerations that follow.

Convergent clinical, therapeutic, and system-level shifts that are redefining patient pathways, treatment paradigms, and access dynamics in Kaposi sarcoma care

The Kaposi sarcoma landscape is undergoing several convergent shifts that collectively reshape clinical pathways and commercial opportunity. Advances in HIV diagnosis and earlier antiretroviral therapy initiatives have altered the incidence profile in many high-income settings, thereby changing the composition of patient cohorts seen in oncology and dermatology clinics. Concurrently, the expansion of transplant medicine and the increased use of potent immunosuppressants have elevated the relative prominence of iatrogenic cases, which often require different management approaches and closer coordination with transplant teams.

At the therapeutic frontier, traditional cytotoxic approaches, including liposomal anthracyclines and taxanes, remain foundational for many patients, while immunomodulatory strategies are gaining traction. Checkpoint inhibitors and interferon alpha have demonstrated activity in specific contexts, prompting exploratory trials and compassionate-use programs that seek to define biomarkers of response. In parallel, radiation therapy techniques - from precise external beam modalities to focused brachytherapy - offer palliation and local disease control with improving toxicity profiles, and surgical interventions continue to play a role in symptom management and cosmetic outcomes.

On the systems side, telemedicine and decentralized care models are improving access to specialist consultations, particularly for cutaneous and mucosal disease. Supply chain resilience and regulatory harmonization are emerging strategic priorities as manufacturers and payers alike navigate global procurement challenges. Taken together, these shifts demand adaptable clinical guidelines, proactive payer engagement, and investment in diagnostics and biomarkers to guide therapeutic choice and measure meaningful patient outcomes.

How 2025 tariff adjustments in the United States are influencing supply chains, procurement strategies, clinical operations, and access dynamics for Kaposi sarcoma treatments

The introduction of cumulative United States tariff measures in 2025 has created ripple effects across pharmaceutical supply chains, procurement strategies, and pricing dynamics relevant to Kaposi sarcoma care. Import tariffs on active pharmaceutical ingredients and finished oncology therapies can increase landed costs for liposomal anthracyclines, taxanes, and certain supportive care agents, which in turn pressures hospital formularies and acute care budgets. As a result, procurement teams are reassessing sourcing strategies, including greater emphasis on contract diversification, nearshoring, and longer-term supplier agreements to mitigate price volatility and delivery risk.

These tariff-induced cost pressures also influence clinical operations. Health systems facing constrained budgets may prioritize shorter-course local therapies or optimize resource utilization through outpatient administration models and utilization of lower-cost generic alternatives where clinically acceptable. In response, manufacturers and distributors are exploring alternative packaging, patient support programs, and value-based contracting approaches designed to preserve access while containing net treatment costs. Regulatory pathways for biosimilars and generics may gain renewed attention, as stakeholders seek clinically equivalent options with more predictable price trajectories.

Moreover, tariffs can affect the pace and geography of clinical research. Sponsors may relocate manufacturing for trial supplies, renegotiate international trial budgets, or concentrate studies in jurisdictions with more favourable trade terms. For clinicians and payers, the net effect is a heightened need for transparent cost-effectiveness data and real-world evidence that demonstrates comparative value. Ultimately, while tariffs are one of many economic levers shaping the oncology ecosystem, they underscore the importance of strategic supply chain planning and collaborative stakeholder approaches to safeguard patient access to established and emerging therapies.

An actionable multidimensional segmentation framework linking patient populations, therapeutic modalities, disease types, distribution sites, end users, and distribution channels for precise strategy

A nuanced segmentation framework is essential to understand therapeutic needs and design targeted interventions. Patient population stratification clarifies clinical drivers by distinguishing individuals living with HIV, immunocompromised non-HIV patients, and transplant recipients; each group presents distinct disease trajectories, comorbidity profiles, and tolerance of systemic therapies. For example, people living with HIV often require integrated antiretroviral coordination and opportunistic infection management, while transplant recipients necessitate a careful balance between antitumor efficacy and graft preservation.

Treatment modality segmentation provides a practical lens for clinical and commercial planning by differentiating systemic and local approaches. Chemotherapy remains anchored by liposomal anthracyclines and taxanes, which deliver meaningful disease control in many scenarios. Immunotherapy pathways are evolving around checkpoint inhibitors and interferon alpha, which represent divergent mechanisms of immune engagement and require different biomarker and safety considerations. Radiation therapy, whether administered as brachytherapy or external beam, offers localized control and symptom relief, while surgical interventions span cosmetic procedures and lesion excision that address both function and quality of life. These modality distinctions inform trial design, reimbursement discussions, and specialty service development.

Disease type segmentation retains clinical importance: classic, endemic, epidemic, and iatrogenic forms of Kaposi sarcoma differ in natural history, demographic distribution, and care pathways, and this heterogeneity affects screening, diagnostic intensity, and therapeutic aggressiveness. Distribution site-based differentiation - cutaneous, mucosal, and visceral involvement - guides urgency of intervention, imaging strategies, and multidisciplinary coordination. Finally, end user segmentation describes where care and dispensing occur, with hospitals, outpatient facilities, and specialty clinics each playing a role in delivering complex regimens, supportive care, and follow-up. Distribution channel distinctions between hospital pharmacies, online pharmacies, and retail pharmacies also shape patient access and adherence, especially for oral supportive agents and adjunctive medications. Integrating these segmentation axes yields a multidimensional view that supports tailored clinical protocols, commercial prioritization, and region-specific access strategies.

A regional view of Kaposi sarcoma that aligns epidemiology, health system capacity, and access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a powerful influence on clinical practice, access, and the evolution of therapeutic options. In the Americas, high-resource settings have seen declines in epidemic Kaposi sarcoma thanks to widespread antiretroviral availability, yet pockets of disease persist among underserved populations and late presenters. Consequently, there is concentrated demand for integrated HIV-oncology services, outpatient infusion capacity for liposomal chemotherapies, and supportive care networks that address comorbidities and social determinants of health. North-South disparities within the region also require targeted outreach and funding mechanisms to ensure continuity of care.

In Europe, Middle East & Africa the picture is heterogeneous, with Western European health systems emphasizing specialty oncology pathways and reimbursement-based access, while parts of Africa contend with a higher disease burden, resource limitations, and diagnostic constraints. The Middle East presents a mix of advanced tertiary care centers and varying access levels, which underscores the importance of adapting clinical guidelines to local capacity and strengthening regional supply chains for essential therapies. Collaborative public health initiatives, diagnostic scale-up, and training programs for multidisciplinary teams are pivotal to narrowing outcome gaps.

Asia-Pacific encompasses a diverse array of health system maturities, from highly specialized urban centers that support clinical trials and advanced radiation techniques to rural areas where diagnosis and sustained antiretroviral delivery remain the core challenge. This region is also notable for rapid growth in local manufacturing capabilities and increasing participation in multinational trials, which can influence treatment availability and cost structures. Across all regions, tailored strategies that account for epidemiology, health infrastructure, regulatory environments, and cultural factors will be essential for improving patient outcomes and enabling efficient adoption of new therapies.

How pharmaceutical and biotechnology strategies are aligning R&D, manufacturing, partnerships, and patient support to address clinical demands and access realities in Kaposi sarcoma

Company-level dynamics reflect a blend of legacy oncology portfolios, emerging immunotherapy programs, and specialty biotechs focused on viral oncology and targeted delivery systems. Established pharmaceutical entities with experience in liposomal formulation and cytotoxic agents continue to support standard-of-care regimens and maintain manufacturing scale for liposomal anthracyclines and taxane products. At the same time, biopharmaceutical innovators are pursuing immune-modulating approaches, biomarker-driven indications, and next-generation delivery platforms that aim to improve efficacy and tolerability for Kaposi sarcoma patients.

Strategically, many companies are pursuing collaborative models that combine clinical expertise, diagnostic capabilities, and regional distribution partners to accelerate market entry and support clinicians in complex care settings. Licensing agreements and localized manufacturing are being evaluated to reduce exposure to supply chain friction and to meet region-specific regulatory requirements. In parallel, commercial teams are increasingly focused on developing patient support services, hub-and-spoke distribution models, and value demonstration programs that align clinical outcomes with payer expectations.

From an R&D perspective, there is growing interest in platform technologies that can be repurposed across virally driven malignancies, as well as in companion diagnostics that identify patients most likely to benefit from immune-driven therapies. Companies that effectively marry translational research with pragmatic access strategies will be better positioned to capture clinical relevance and long-term value in this therapeutic niche.

Practical strategic actions for companies to strengthen supply chains, prioritize translational research, and align commercial models with clinical realities in Kaposi sarcoma

Industry leaders should pursue a set of pragmatic, actionable measures that preserve patient access while advancing therapeutic innovation. First, strengthening supply chain resilience through diversified sourcing, regional manufacturing partnerships, and long-term procurement contracts can mitigate tariff and geoeconomic risks while ensuring consistent availability of core agents such as liposomal anthracyclines and taxanes. Second, investing in translational biomarker programs and pragmatic clinical studies that clarify which patients benefit from checkpoint inhibitors or interferon alpha will de-risk regulatory engagement and support targeted reimbursement discussions.

Third, aligning commercial models with health system realities is essential; this means designing flexible access programs that accommodate hospital formularies, outpatient infusion centers, and specialty clinics, and that can be adapted across jurisdictional reimbursement frameworks. Fourth, building clinician and payer education initiatives around optimal sequencing of systemic, radiation, and surgical interventions will facilitate evidence-based care pathways and reduce unwarranted practice variation. Fifth, forming cross-sector partnerships with transplant centers, HIV care networks, and dermatology clinics can create integrated care pathways that address comorbidity management and long-term follow-up.

Finally, organizations should prioritize patient-centric metrics, including functional outcomes, symptom control, and quality of life, as core endpoints in trials and real-world studies. By combining supply chain foresight, translational research, adaptive commercial frameworks, and stakeholder engagement, industry participants can both improve patient care and create sustainable pathways for innovation.

A transparent triangulated research methodology combining clinical literature, regulatory analysis, trial registries, and stakeholder interviews to ensure robust and practical insights

This research synthesis was developed using a triangulated methodology that integrates peer-reviewed clinical literature, regulatory guidance documents, publicly available clinical trial registries, and structured interviews with multidisciplinary clinicians and supply chain experts. Literature analysis focused on recent advances in virology, oncology therapeutics, and radiation techniques relevant to Kaposi sarcoma, while regulatory reviews examined indication-specific approvals, compassionate-use policies, and reimbursement frameworks across representative jurisdictions.

Stakeholder engagement included interviews with infectious disease specialists, oncologists, transplant physicians, dermatologists, hospital pharmacists, and procurement leaders to capture real-world treatment pathways, formulary considerations, and operational constraints. Supply chain and commercial discussions were augmented by consultations with distribution partners and specialty pharmacy operators to understand the practical implications of tariff changes and sourcing strategies. Data synthesis emphasized consistency across sources, with conflicting or uncertain evidence explicitly noted and qualitatively assessed.

Limitations of the methodology include variability in regional data availability, heterogeneity of clinical practice across settings, and the evolving nature of clinical trial evidence for emerging immunotherapies. To mitigate these factors, findings were validated through cross-disciplinary review and scenario testing to ensure robustness. The final outputs prioritize clinical relevance, operational feasibility, and strategic applicability for decision-makers seeking actionable insights into the Kaposi sarcoma ecosystem.

A succinct synthesis emphasizing the need for personalized care, resilient supply strategies, and translational investments to improve outcomes in Kaposi sarcoma

Kaposi sarcoma presents complex clinical and commercial challenges that require integrated, evidence-based responses across disciplines and geographies. While antiviral therapies have transformed the prognosis for many patients, the disease endures in distinct populations that demand tailored clinical pathways. The interplay among systemic chemotherapies, emerging immunotherapies, radiation techniques, and surgical options underscores the need for personalized treatment planning and multidisciplinary collaboration.

Economic and policy shifts, including tariff measures and supply chain realignments, add an operational dimension that influences access and procurement strategies. Regional heterogeneity further complicates uniform approaches, calling for locally adapted solutions that reflect epidemiology, health system capacity, and regulatory environments. For industry and clinical stakeholders alike, success will hinge on combining translational science with pragmatic delivery models that protect access, demonstrate value, and respond to patient-centered outcomes.

In closing, the path forward requires coordinated investment in biomarker research, resilient supply chains, and stakeholder engagement that bridges clinical practice and payer expectations. By doing so, the community can both improve individual patient outcomes and create a sustainable framework for advancing therapeutics in this specialized oncology niche.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of PD-1 and PD-L1 immune checkpoint inhibitors for refractory Kaposi sarcoma treatment
  • 5.2. Expansion of affordable generic paclitaxel and liposomal doxorubicin production to serve low-income markets with high Kaposi sarcoma prevalence
  • 5.3. Emergence of topical sirolimus and rapamycin formulations for localized cutaneous Kaposi sarcoma lesion management
  • 5.4. Development of digital teledermatology and mobile imaging platforms for remote monitoring of Kaposi sarcoma progression
  • 5.5. Increasing integration of HHV-8 molecular diagnostics for early detection and personalized management of Kaposi sarcoma
  • 5.6. Initiation of multicenter clinical trials evaluating anti-angiogenic agents and novel thalidomide derivatives in Kaposi sarcoma therapy
  • 5.7. Strategic partnerships between pharmaceutical firms and global health organizations to expand Kaposi sarcoma drug access in Sub-Saharan Africa
  • 5.8. Application of gene editing and viral latency targeting therapies to disrupt HHV-8 persistence in Kaposi sarcoma patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Kaposi Sarcoma Market, by Patient Population

  • 8.1. Hiv Positive Patients
  • 8.2. Immunocompromised Non-Hiv
  • 8.3. Transplant Recipients

9. Kaposi Sarcoma Market, by Treatment Modality

  • 9.1. Chemotherapy
    • 9.1.1. Liposomal Anthracyclines
    • 9.1.2. Taxanes
  • 9.2. Immunotherapy
    • 9.2.1. Checkpoint Inhibitors
    • 9.2.2. Interferon Alpha
  • 9.3. Radiation Therapy
    • 9.3.1. Brachytherapy
    • 9.3.2. External Beam
  • 9.4. Surgery
    • 9.4.1. Cosmetic Surgery
    • 9.4.2. Lesion Excision

10. Kaposi Sarcoma Market, by Disease Type

  • 10.1. Classic
  • 10.2. Endemic
  • 10.3. Epidemic
  • 10.4. Iatrogenic

11. Kaposi Sarcoma Market, by Distribution Site

  • 11.1. Cutaneous
  • 11.2. Mucosal
  • 11.3. Visceral

12. Kaposi Sarcoma Market, by End User

  • 12.1. Hospitals
  • 12.2. Outpatient Facilities
  • 12.3. Specialty Clinics

13. Kaposi Sarcoma Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Kaposi Sarcoma Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Kaposi Sarcoma Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Kaposi Sarcoma Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Johnson & Johnson
    • 17.3.2. Bristol-Myers Squibb Company
    • 17.3.3. Roche Holding AG
    • 17.3.4. Novartis AG
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Merck & Co., Inc.
    • 17.3.7. Gilead Sciences, Inc.
    • 17.3.8. Sanofi S.A.
    • 17.3.9. Takeda Pharmaceutical Company Limited
    • 17.3.10. AbbVie Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. KAPOSI SARCOMA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. KAPOSI SARCOMA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. KAPOSI SARCOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL KAPOSI SARCOMA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HIV POSITIVE PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HIV POSITIVE PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HIV POSITIVE PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HIV POSITIVE PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HIV POSITIVE PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HIV POSITIVE PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOCOMPROMISED NON-HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOCOMPROMISED NON-HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOCOMPROMISED NON-HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOCOMPROMISED NON-HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOCOMPROMISED NON-HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOCOMPROMISED NON-HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TRANSPLANT RECIPIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TRANSPLANT RECIPIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TRANSPLANT RECIPIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TRANSPLANT RECIPIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TRANSPLANT RECIPIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TRANSPLANT RECIPIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LIPOSOMAL ANTHRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LIPOSOMAL ANTHRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LIPOSOMAL ANTHRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LIPOSOMAL ANTHRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LIPOSOMAL ANTHRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LIPOSOMAL ANTHRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TAXANES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TAXANES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TAXANES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY TAXANES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EXTERNAL BEAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EXTERNAL BEAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EXTERNAL BEAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EXTERNAL BEAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COSMETIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COSMETIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COSMETIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COSMETIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COSMETIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY COSMETIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LESION EXCISION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LESION EXCISION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LESION EXCISION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LESION EXCISION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LESION EXCISION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY LESION EXCISION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CLASSIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ENDEMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY EPIDEMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY IATROGENIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY CUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MUCOSAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MUCOSAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MUCOSAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MUCOSAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MUCOSAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY MUCOSAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VISCERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VISCERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VISCERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VISCERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VISCERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY VISCERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY OUTPATIENT FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY OUTPATIENT FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY OUTPATIENT FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY OUTPATIENT FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY OUTPATIENT FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY OUTPATIENT FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL KAPOSI SARCOMA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE KAPOSI SARCOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE KAPOSI SARCOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2018-2024 (USD MILLION)
  • TABLE 322. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION SITE, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST KAPOSI SARCOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA KAPOSI SARCOMA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 329. AFRICA KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 330. AFRICA KAPOSI SARCOMA MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 331. AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 332. AFRICA KAPOSI SARCOMA MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 333. AFRICA KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 334. AFRICA KAPOSI SARCOMA MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 335. AFRICA KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 336. AFRICA KAPOSI SARCOMA MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 337. AFRICA KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 338. AFRICA KAPOSI SARCOMA MARKET SIZE, BY RADIATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 339. AFRICA KAPOSI SARCOMA MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 340. AFRICA KAPOSI SARCOMA MARKET SIZE, BY